Quest Diagnostics (DGX) has successfully completed key
Mergers & Acquisitions (M&As), showcasing growth and reinforcing market presence amid competition. Several banks and investment firms have adjusted their holdings in DGX. The company is due to release its
Q2 2024 financial results on July 23, 2024. A strategic acquisition of
Select PathAI Diagnostics' Lab Assets from PathAI is anticipated to hasten the adoption process. Furthermore, the company's stock performance has been robust, and they have declared a
quarterly cash dividend. A new buyout has bolstered their cancer diagnosis capabilities. With a collaborative effort, DGX and Instacart aim to lessen food insecurity across the U.S. In addition, DGX continues to make strides in digital pathology through new deals. It has also launched
MelaNodal Predict™ Test, a proprietary test that personalizes melanoma risk prediction. While the company's testing sales have seen a dip due to competition, their financial performance and overall market influence remain strong.
Quest Diagnostics DGX News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sun, 23 Jun 2024 11:29:45 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -5
